A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
a study on Breast Cancer
Breast Cancer PI3K (phosphoinositide 3-kinase) mTOR (mechanistic target of rapamycin) PI3K/mTOR metastatic breast cancer (MBC) ER+ (estrogen receptor positive) HER2- (human epidermal growth factor receptor 2 negative) Breast Neoplasms Letrozole Fulvestrant Palbociclib Gedatolisib
Lead Scientist at UCSF
- Hope Rugo
Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer.
- in progress, not accepting new patients
- Start Date
- Completion Date
- To obtain contact information for a study center near you, click here.
- Phase 1
- Study Type
- Last Updated